{
    "clinical_study": {
        "@rank": "26856", 
        "arm_group": {
            "arm_group_label": "Icotinib", 
            "arm_group_type": "Experimental", 
            "description": "Icotinib is administered orally 125 mg three times per day continuously for four weeks"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether Icotinib is efficient and safe in\n      treating advanced non-small cell lung cancer (NSCLC) patients with hepatic insufficiency."
        }, 
        "brief_title": "Icotinb in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Hepatic Insufficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients with hepatic insufficiency is an important subgroup of who receive EGFR TKIs.\n      Phase I/II studies showed that Icotinib has good security. Based on the above\n      considerations, this single-arm, open-label study is designed to evaluate the safety of\n      icotinib 125mg three times daily for histologically or cytologically confirmed NSCLC\n      patients with hepatic insufficiency."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed diagnosis of IIIB/IV stage NSCLC patients\n             who are not suitable for surgery or radiotherapy\n\n          -  ECOG performance status points (PS) is 0-2\n\n          -  Liver function:\n\n        A (mild hepatic dysfunction):\n\n        A1)  total bilirubin within normal limit (ULN), while AST> ULN;\n\n        A2)  total bilirubin within1.0-1 .5 \u00d7 ULN;\n\n        B (moderate hepatic dysfunction): total bilirubin within1.5-3 .0 \u00d7 ULN\n\n          -  No malabsorption or other gastrointestinal disorders effecting drug absorption\n\n          -  Life expectancy: more than 12 weeks.\n\n        Exclusion Criteria:\n\n          -  Previous usage of  HER/EGFR inhibitors or other target molecule drugs ( small\n             molecule drugs or monoclonal antibody therapy )\n\n          -  Patients requires liver shunt , stent placement, or radiotherapy when 2 weeks before\n             the start of the study or research process .\n\n          -  Patients with active hepatitis and cirrhosis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02062515", 
            "org_study_id": "BD-IC-IV51"
        }, 
        "intervention": {
            "arm_group_label": "Icotinib", 
            "description": "Icotinib is administered orally 125 mg three times per day continuously for four weeks", 
            "intervention_name": "icotinib", 
            "intervention_type": "Drug", 
            "other_name": [
                "BPI-2009", 
                "Commana"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510060"
                }, 
                "name": "Sun Yat-sen Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety Assessment of Icotinb in Advanced NSCLC Patients With Hepatic Insufficiency: A Multi-center, Open-label, Single-arm Study", 
        "overall_official": {
            "affiliation": "Sun Yat-sen Cancer Center", 
            "last_name": "Hao Long, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants with Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02062515"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Betta Pharmaceuticals Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Betta Pharmaceuticals Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}